bombesin BRS-3 receptor agonists (GSK)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namebombesin BRS-3 receptor agonists (GSK)
Drug Alias Namebombesin BB3 receptor agonists (GSK)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBombesin receptor subtype-3 agonists
TargetsBombesin receptor subtype-3
Therapy Area/IndicationsObesityDiabetes MellitusNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsObesityDiabetes MellitusNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A